


CURRICULUM VITAE

Full Name:	Lopez-Brignoni	Evelyn	M
	Last Name	First Name	Middle Initial
Professional Mailing Address: (Include institution name.)			
IMIC, Inc. 18320 Franjo Rd Palmetto bay FL 33157 305-338-0568, fax 786-536-9016			
Email: evelyn@aktamedika.com			
Academic Qualifications (most current date first)			
<u>Degree/Certification</u>	<u>Date (YYYY)</u>	<u>Institution, Country</u>	
GCP Course	2015	<u>CITI, USA</u>	
Board certified Child and Adolescent Psychiatry	<u>1987</u>	<u>American Board of Psychiatry and Neurology, USA</u>	
Board certified Psychiatry	<u>1986</u>	<u>American Board of Psychiatry and Neurology, USA</u>	
Fellowship Child and Adolescent Psychiatry	<u>1981-1983</u>	<u>Bronx Municipal Hospital, NY USA</u>	
Residency Psychiatry	<u>1979-1981</u>	<u>NYU Bellvue, NY, USA</u>	
Internship Psychiatry	<u>1977-1979</u>	<u>SUNY at Stony Brook, NY USA</u>	
MD	<u>1973-1977</u>	<u>University of Puerto Rico, School of Medicine, PR USA</u>	
Current and Previous 4 Relevant Positions Including Academic Appointments (most current date first):			
<u>Start and End Dates</u>	<u>Title</u>	<u>Institution or Company, State/Province/Country</u>	
<i>2014-current</i>	Principal Investigator/ Evaluator	<i>IMIC Inc, Palmetto bay FL USA</i>	
<i>2012-2014</i>	Sub-Investigator Evaluator	<i>IMIC, Inc, Miami Beach FL USA</i>	
<i>1983-current</i>	Psychiatrist, Private practice	Dr Evelyn Lopez-Brignoni MD, Coral Gables FL USA	
Brief Summary of Relevant Clinical Research Experience in last 5 years:			
<p><i>Participation in 10 sponsored controlled trials as PI and 17 as Sub-I since 1983 in the field of depression, pain management, anxiety, women sexual health, Autism specter, ADHD, Alzheimer's and schizophrenia . More current trials listed below.</i></p> <p><u>2017- E2609-G000-302: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease as PI</u></p> <p><u>2016 - 15-AVP-786-303 - A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type.as a PI</u></p> <p>2016 - A Phase 3, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterium modified dextromethorphan hydrobromide/quinidine sulfate) for the treatment of agitation in patients with dementia of Alzheimer's type as PI.</p> <p>2015 - A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer's Disease as PI</p> <p>2015 - A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder as PI</p> <p>2015- An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder as PI</p> <p>2014- A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-</p>			

CURRICULUM VITAE

group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer's Disease as PI
 2014- A randomized, double-blind, placebo-controlled, 13-week study of ds-5565 for treatment of diabetic peripheral neuropathic pain as SI
 2013 – Phase 2, Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy as SI
 2013- A randomized double-blind placebo controlled parallel group study of the efficacy and safety of Pregabalin (bid) in subjects with post-traumatic peripheral neuropathic pain as PI
 2011 - Lurasidone - A 6-week Study of Patients With Bipolar I Depression As PI
 2012 - A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) as PI

2009 - Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness (SMART-M) as Sub-I

Medical License/ID Number:	ME54458	Licensed in State/Province/ Country:	FL/USA
Medical License Expiration date:	01/31/2019	FL	
Signature:			Signature Date: (dd-Mmm-yyyy) 27 - Mar - 2017